Kane Biotech (KNE) AI Stock Analysis

• Market Cap: C$5.02M
• Dividend Yield: N/A
• Average Volume (3M): 112.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 167,346,560
• 10 Day Avg. Volume: 120,057
• 30 Day Avg. Volume: 112,955
• PEG Ratio: 0.13
• Price to Book (P/B): -9.04
• Price to Sales (P/S): 7.08
• P/FCF Ratio: -3.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.03 ▲(13.33% Upside)

Kane Biotech's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenue, high leverage, and cash flow constraints. The technical analysis provides mixed signals, with bearish trends and potential overbought conditions. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield.

Positive Factors

Innovative Product Portfolio

The company's focus on innovative antimicrobial technologies positions it well to address biofilm-related challenges, offering a competitive edge in healthcare and industrial applications.

Diverse Revenue Streams

Multiple revenue streams, including product sales and licensing, provide a stable income base and reduce reliance on a single market, enhancing financial resilience.

Market Demand for Biofilm Solutions

Growing demand for biofilm solutions in healthcare and industrial sectors supports long-term revenue growth potential and market expansion opportunities.

Negative Factors

Declining Revenue

Persistent revenue decline indicates challenges in market penetration and product adoption, which could hinder long-term growth and profitability.

High Leverage

High leverage poses financial risks, limiting the company's ability to invest in growth opportunities and increasing vulnerability to economic downturns.

Cash Flow Constraints

Cash flow constraints indicate operational inefficiencies and insufficient cash generation, which could impact the company's ability to sustain operations and fund future initiatives.

Kane Biotech Business Overview & Revenue Model

Company Description

Kane Biotech (KNE) is a biotechnology company focused on the development of innovative antimicrobial technologies aimed at addressing biofilm-related challenges across various sectors, including healthcare, veterinary, and industrial applications. The company specializes in creating patented products designed to prevent and treat biofilm infections, which are significant contributors to chronic infections and device-related complications. Kane Biotech's core products include wound care solutions and antimicrobial coatings that enhance the efficacy of medical devices.

How the Company Makes Money

Kane Biotech generates revenue through multiple streams, including the sale of its proprietary antimicrobial products to healthcare providers, veterinary clinics, and industrial clients. The company also engages in licensing agreements, allowing other manufacturers to use its technology in their products, which provides a steady royalty income. Additionally, Kane Biotech may partner with larger pharmaceutical or medical device companies for collaborative research and development projects, which can lead to milestone payments and shared revenue from resulting products. The company’s focus on addressing biofilm-related issues positions it to capitalize on growing market demand in both healthcare and industrial applications.

Kane Biotech Financial Statement Overview

Summary

Kane Biotech is facing significant financial challenges. The income statement shows declining revenue and persistent losses, the balance sheet reflects high leverage and negative equity, and the cash flow statement indicates cash flow constraints. The company needs to address its operational inefficiencies and financial instability to improve its financial health and sustainability.

Income Statement

Kane Biotech's income statement reveals significant challenges. The company has experienced a substantial decline in revenue growth, with a negative growth rate of -24.27% in the TTM period. Profitability metrics are concerning, with a negative net profit margin of -105.22% and negative EBIT and EBITDA margins, indicating ongoing operational losses. The gross profit margin has also decreased from previous periods, reflecting pressure on cost management. Overall, the income statement highlights severe profitability issues and declining revenue trends.

Balance Sheet

The balance sheet of Kane Biotech shows financial instability. The company has a negative stockholders' equity, leading to a negative debt-to-equity ratio of -11.09 in the TTM period, indicating high leverage and financial risk. The return on equity is positive but misleading due to negative equity. The equity ratio is not calculable due to negative equity, further emphasizing the company's weak financial position. Overall, the balance sheet reflects high leverage and financial distress.

Cash Flow

Kane Biotech's cash flow statement indicates cash flow challenges. The free cash flow growth rate is negative at -31.93% in the TTM period, showing a decline in cash generation. The operating cash flow to net income ratio is negative, reflecting insufficient cash flow to cover net losses. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is marginally covering net losses. Overall, the cash flow statement highlights cash flow constraints and operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.85M	2.08M	148.98K	156.73K	1.61M	1.34M
Gross Profit	468.47K	872.10K	109.47K	1.41M	568.44K	526.86K
EBITDA	-2.83M	-3.71M	-3.23M	-2.95M	-4.25M	-3.65M
Net Income	-1.95M	-3.02M	-5.03M	-3.89M	-4.60M	-3.72M
Balance Sheet
Total Assets	3.81M	2.49M	5.68M	5.62M	6.13M	5.04M
Cash, Cash Equivalents and Short-Term Investments	1.61M	358.81K	749.25K	1.10M	1.15M	1.01M
Total Debt	2.61M	2.29M	9.26M	6.86M	4.71M	2.25M
Total Liabilities	4.05M	4.12M	14.09M	9.76M	7.70M	3.96M
Stockholders Equity	-234.99K	-1.63M	-10.56M	-6.52M	-3.89M	-1.49M
Cash Flow
Free Cash Flow	-2.94M	-4.14M	-3.23M	-3.13M	-2.64M	-4.07M
Operating Cash Flow	-2.83M	-4.11M	-3.22M	-3.04M	-2.29M	-3.94M
Investing Cash Flow	-62.50K	10.27M	-116.14K	-107.55K	-373.55K	-166.11K
Financing Cash Flow	3.50M	-7.69M	2.98M	3.10M	2.81M	4.28M

Kane Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 44.22 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.

Kane Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KNE	44 Neutral	C$5.02M	-2.46	―	―	―	―
MOOD	42 Neutral	C$5.69M	-7.05	-32.09%	―	-50.89%	-32.33%
APS	37 Underperform	C$5.56M	-0.19	391.94%	―	―	90.81%
XRTX	36 Underperform	C$5.85M	-1.28	-96.61%	―	―	-1939.32%
BIOV	29 Underperform	C$6.41M	-0.99	―	―	―	25.09%

Kane Biotech Corporate Events

Kane Biotech Reports Q3 2025 Results Amid Strategic Progress in Wound Care Market

Kane Biotech announced its third quarter 2025 financial results, revealing a significant decline in revenue and gross profit compared to the previous year, largely due to the termination of key agreements. Despite the financial setbacks, the company is making strides in its strategic initiatives, particularly in the U.S. wound care market. Kane has exceeded enrollment targets for its revyve Antimicrobial Wound Gel U.S. Case Series Studies and presented promising clinical data at major conferences, demonstrating the product’s efficacy in diabetic foot ulcer healing and burn wound infection control. The company is actively working to rebuild its U.S. distributor network and has submitted a 510(k) clearance application to the FDA for its wound cleanser, aiming to expand its market presence and improve patient outcomes.

Kane Biotech Launches $800,000 Private Placement Offering

Kane Biotech Inc. has announced a non-brokered private placement offering of up to 16 million common shares at $0.05 per share, aiming to raise up to $800,000. The proceeds will be used for working capital and general corporate purposes, with the offering expected to close around December 17, 2025, pending necessary approvals. This move is part of Kane Biotech’s strategy to strengthen its financial position and support its ongoing operations in the wound care industry.

Kane Biotech’s revyve Gel Shows Promising Results in Wound Care

Kane Biotech recently presented promising clinical and pre-clinical data for its revyve Antimicrobial Wound Gel and Gel Spray at major U.S. medical conferences. The data showed significant improvements in diabetic foot ulcer healing and burn wound infection control, with the revyve products outperforming the standard of care by achieving a 97% reduction in wound area within four weeks and complete closure within 12 weeks. These findings highlight revyve’s potential to enhance wound care outcomes and support Kane Biotech’s strategy to impact the U.S. wound care market.

Kane Biotech Submits FDA Clearance for New Wound Cleanser

Kane Biotech has submitted a 510(k) clearance to the U.S. FDA for its new revyve Antimicrobial Wound Cleanser, expanding its revyve product line. This product is designed to aid in wound management by cleansing wounds, reducing bacterial load, and removing loose material. The U.S. market for wound cleansers is substantial, with an annual size exceeding $200 million USD, indicating a significant opportunity for Kane Biotech to enhance its market presence and impact stakeholders positively.

Kane Biotech Exceeds Enrollment Target in U.S. Studies for revyve® Wound Care Products

Kane Biotech has successfully completed enrollment for its U.S. Case Series Studies of the revyve® Antimicrobial Wound Gel and Spray, surpassing their target with 28 participants. This development highlights the growing interest from clinicians and patients in the U.S., potentially enhancing the company’s position in the wound care market by demonstrating the effectiveness of their products in treating challenging wounds and burns.